Health Care & Life Sciences » Biotechnology | Regulus Therapeutics Inc.

Regulus Therapeutics Inc. | Key People and Executives

Joseph P. Hagan
President, Chief Executive Officer & Director
Stelios B. Papadopoulos
Chairman
Kathryn J. Collier
Independent Director
Pascale Witz
Independent Director
Hugh Rosen
Independent Director
David Baltimore
Independent Director
William H. Rastetter
Independent Director
Joseph P. Hagan
President, Chief Executive Officer & Director
Daniel R. Chevallard
Chief Financial & Accounting Officer
Timothy M. Wright
Chief Research & Development Officer
Mary Yaroshevsky-Glanville
Senior Vice President-Human Capital
Christopher Aker
Secretary & Vice President-Legal Affairs
Stelios B. Papadopoulos
Chairman
Kathryn J. Collier
Independent Director
Pascale Witz
Independent Director
Hugh Rosen
Independent Director
David Baltimore
Independent Director
William H. Rastetter
Independent Director

About Regulus Therapeutics

View Profile
Address
10628 Science Center Drive
San Diego California 92121
United States
Employees -
Website http://www.regulusrx.com
Updated 07/08/2019
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.